Risk factors, prevention, and treatment of corticosteroid-induced osteoporosis in adults

Orthopedics

Volumn 31, Issue 8, 2008, Pages 768-

  Ruf, Kathryn M ^a   Johnson, Nicole K ^a   Clifford, Timothy ^b   Smith, Kelly M ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BECLOMETASONE; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; CITRATE CALCIUM; CORTICOSTEROID; DEXAMETHASONE; ETIDRONIC ACID; HYDROCORTISONE; METHYLPREDNISOLONE; PARATHYROID HORMONE; PREDNISOLONE; PREDNISONE; RISEDRONIC ACID; SALCATONIN; VITAMIN D; BONE DENSITY CONSERVATION AGENT; GLUCOCORTICOID;

APOPTOSIS; ASTHMA; AUTOIMMUNE DISEASE; BONE DENSITY; BONE NECROSIS; CLINICAL TRIAL; CORTICOSTEROID INDUCED OSTEOPOROSIS; CORTICOSTEROID THERAPY; ELECTROLYTE DISTURBANCE; ENTERITIS; HUMAN; HYPERGLYCEMIA; LIFESTYLE MODIFICATION; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; PATHOPHYSIOLOGY; PROPHYLAXIS; REVIEW; RISK FACTOR; TREATMENT DURATION; ADULT; ARTICLE; CHEMICALLY INDUCED DISORDER; LIFESTYLE; OSTEOPOROSIS;

ADULT; BONE DENSITY CONSERVATION AGENTS; CALCITONIN; DIPHOSPHONATES; GLUCOCORTICOIDS; HUMANS; LIFE STYLE; OSTEOPOROSIS; PARATHYROID HORMONE; RISK FACTORS;

EID: 55449091448     PISSN: 01477447     EISSN: None     Source Type: Journal    
DOI: 10.3928/01477447-20080801-29     Document Type: Review

References (39)

1. Gudbjornsson B, Juliusson UI, Gudjonsson FV. Prevalence of long term steroid treatment and the frequency of decision making to prevent steroid induced osteoporosis in daily clinical practice. Ann Rheum Dis. 2002; 61:32-36. (Pubitemid 34074836)
2. Steinbuch M, Youket TE, Cohen S. Oral glucocorticoid use is associated with an increased risk of fracture. Osteoporos Int. 2004; 15(4):323-328. (Pubitemid 38543952)
3. Klein RG, Arnaud SB, Gallagher JC, Deluca HF, Riggs BL. Intestinal calcium absorption in exogenous hypercortisonism. Role of 25-hydroxyvitamin D and corticosteroid dose. J Clin Invest. 1977; 60(1):253-259. (Pubitemid 8145163)
4. Morris HA, Need AG, O'Loughlin PD, Horowitz M, Bridges A, Nordin BE. Malabsorption of calcium in corticosteroid-induced osteoporosis. Calcif Tissue Int. 1990; 46(5):305-308. (Pubitemid 20161771)
5. Tamura Y, Okinaga H, Takami H. Glucocorticoid-induced osteoporosis. Biomed Pharmacother. 2004; 58(9):500-504. (Pubitemid 39423597)
6. Migliaccio S, Brama M, Fornari R, Greco EA, Spera G, Malavolta N. Glucocorticoid-induced osteoporosis: an osteoblastic disease. Aging Clin Exp Res. 2007; 19(3 suppl):5-10.
7. Weinstein RS, Jilka RL, Parfitt AM, Manolagas SC. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J Clin Invest. 1998; 102(2):274-282. (Pubitemid 28335186)
8. Jia D, O'Brien CA, Stewart SA, Manolagas SC, Weinstein RS. Glucocorticoids act directly on osteoclasts to increase their life span and reduce bone density. Endocrinology. 2006; 147(12):5592-5599. (Pubitemid 44833476)
9. Weinstein RS, Chen JR, Powers CC, et al. Promotion of osteoclast survival and antagonism of bisphosphonate-induced osteoclast apoptosis by glucocorticoids. J Clin Invest. 2002; 109(8):1041-1048. (Pubitemid 34408579)
10. Delany AM, Gabbitas BY, Canalis E. Cortisol downregulates osteoblast alpha 1 (I) procollagen mRNA by transcriptional and posttranscriptional mechanisms. J Cell Biochem. 1995; 57(3):488-494.
11. Stellon AJ, Webb A, Compston JE. Bone histomorphometry and structure in corticosteroid treated chronic active hepatitis. Gut. 1988; 29(3):378-384. (Pubitemid 18082156)
12. Naganathan V, Jones G, Nash P, Nicholson G, Eisman J, Sambrook PN. Vertebral fracture risk with long-term corticosteroid therapy: prevalence and relation to age, bone density, and corticosteroid use. Arch Intern Med. 2000; 160(19):2917-2922. (Pubitemid 32009048)
13. Van Staa TP, Laan RF, Barton IP, Cohen S, Reid DM, Cooper C. Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum. 2003; 48(11):3224-3229. (Pubitemid 37409336)
14. O'Brien CA, Jia D, Plotkin LI, et al. Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength. Endocrinology. 2004; 145(4):1835-1841. (Pubitemid 38402392)
15. van Staa TP. The pathogenesis, epidemiology and management of glucocorticoid-induced osteoporosis. Calcif Tissue Int. 2006; 79(3):129-137. (Pubitemid 44440440)
16. Sambrook PN. How to prevent steroid induced osteoporosis. Ann Rheum Dis. 2005; 64(2):176-178. 16. (Pubitemid 40193606)
17. van Staa TP, Leufkens HG, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int. 2002; 13(10):777-787. (Pubitemid 36336722)
18. Compston J, Barlow D, Brown P, et al. Glucocorticoid-induced osteoporosis: guidelines for prevention and treatment. London, England: Royal College of Physicians, 2002. http://www.rcplondon.ac.uk/pubs/books/ glucocorticoid/Glucocorticoid.pdf. Accessed July 24, 2008.
19. Medici TC, Ruegsegger P. Does alternate-day cloprednol therapy prevent bone loss? A longitudinal double-blind, controlled clinical study. Clin Pharmacol Ther. 1990; 48(4):455-466. (Pubitemid 20362280)
20. Goldstein MF, Fallon JJ Jr, Harning R. Chronic glucocorticoid therapy-induced osteoporosis in patients with obstructive lung disease. Chest. 1999; 116(6):1733-1749. (Pubitemid 30012719)
21. Leone FT, Fish JE, Szefler SJ, West SL. Systematic review of the evidence regarding potential complications of inhaled corticosteroid use in asthma: collaboration of American College of Chest Physicians, American Academy of Allergy, Asthma, and Immunology, and American College of Allergy, Asthma, and Immunology. Chest. 2003; 124(6):2329-2340. (Pubitemid 38010606)
22. Recommendations for the Prevention and Treatment of Glucocorticoid- Induced Osteoporosis. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis. Arthritis Rheum. 2001; 44(7):1496-1503.
23. Dawson-Hughes B, Lindsay R, Khosla S, et al. Clinician's Guide to Prevention and Treatment of Osteoporosis. Washington, DC: National Osteoporosis Foundation, 2008. http://www.nof.org/professionals/NOF-Clinicians-Guide.pdf. Accessed July 24, 2008.
24. Buckley LM, Leib ES, Cartularo KS, Vacek PM, Cooper SM. Calcium and vitamin D3 supplementation prevents bone loss in the spine secondary to low-dose corticosteroids in patients with rheumatoid arthritis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1996; 125(12):961-968.
25. DeLuca HF. Overview of general physiologic features and functions of vitamin D. Am J Clin Nutr. 2004; 80:1689S-1696S.
26. Lacey CF, Armstrong LL, Goldman MP, et al. Drug Information Handbook. 15th ed. Hudson, OH: Lexi-Comp; 2007:1879.
27. Plotkin LI, Weinstein RS, Parfitt AM, Roberson PK, Manolagas SC, Bellido T. Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J Clin Invest. 1999; 104(10):1363-1374.
28. Adachi JD, Bensen WG, Brown J, et al. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med. 1997; 337(6):382-387. (Pubitemid 27328368)
29. Cohen S, Levy RM, Keller M, et al. Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum. 1999; 42(11):2309-2318. (Pubitemid 30333410)
30. Reid DM, Hughes RA, Laan RF, et al. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study. J Bone Miner Res. 2000; 15(6):1006-1013.
31. Roux C, Oriente P, Laan R, et al. Randomized trial of effect of cyclical etidronate in the prevention of corticosteroid-induced bone loss. Ciblos Study Group. J Clin Endocrinol Metab. 1998; 83(4):1128-1133. (Pubitemid 28496380)
32. Saag KG, Emkey R, Schnitzer TJ, et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med. 1998; 339(5):292-299.
33. Wallach S, Cohen S, Reid DM, et al. Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int. 2000; 67(4):277-285. (Pubitemid 30736856)
34. Adachi JD, Saag KG, Delmas PD, et al. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum. 2001; 44(1):202-211. (Pubitemid 32113136)
35. Adachi JD, Bensen WG, Bell MJ, et al. Salmon calcitonin nasal spray in the prevention of corticosteroid-induced osteoporosis. Br J Rheumatol. 1997; 36(2):255-259. (Pubitemid 27343276)
36. Sambrook P, Birmingham J, Kelly P, et al. Prevention of corticosteroid osteoporosis. A comparison of calcium, calcitriol, and calcitonin. N Engl J Med. 1993; 328(24):1747-1752. (Pubitemid 23170124)
37. Cranney AWV, Adachi JD, Homik J, et al. Calcitonin for the treatment and prevention of corticosteroid-induced osteoporosis. Cochrane Database Syst Rev. 2000; (2):CD001983.
38. Manolagas SC, Weinstein RS. New developments in the pathogenesis and treatment of steroid-induced osteoporosis. J Bone Miner Res. 1999; 14(7):1061-1066. (Pubitemid 29314048)
39. Lane NE, Sanchez S, Modin GW, Genant HK, Pierini E, Arnaud CD. Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial. J Clin Invest. 1998; 102(8):1627-1633. (Pubitemid 28492231)